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metric tests (frequency, factor analysis, reliability tests) were used to verify the rele-
vance and determinacy of the attributes. Repertory grid analysis was used to identify 
the constructs used by patients to characterize overweight and obesity therapy. 
Respondents were presented with cards outlining the preference dimensions and asked 
to rank the most relevant dimensions in order of relevance. RESULTS: The mapping 
of attributes and endpoints resulted in categories that emerged as relevant spanning 
from therapy attributes as technical care, access, empowerment and interpersonal care. 
The factor analysis of the attributes resulted in 8 factors with a KMO of 74.8; chron-
bachs alpha between 0.878 and 0.552 and a total mean square of 55.416%. The reper-
tory grid and ranking resulted in ﬁve patient-relevant endpoints (e.g. functional status, 
side effects, outcome and risk factors). CONCLUSIONS: The novelty of this analysis 
is the combination of qualitative and quantitative methods to build a conceptual map 
of patient-centered outcomes that can be used to plan comprehensive assessment of 
patient preferences in overweight and obesity therapy. The map concludes important 
attributes and endpoints and makes it possible to sort them in categories and subcat-
egories. Theoretical issues concerning the nature of attributes and their interrelation-
ships are raised and the implications for the measurement of patient preferences are 
discussed.
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OBJECTIVES: This study assessed the subjective drug valuations of two opioids. This 
valuation may contribute to a better understanding of beneﬁciary preferences unre-
lated to drug effectiveness. METHODS: This exploratory, randomized, double-blind, 
placebo-controlled, 5-way crossover study compared the subjective and objective 
effects of equianalgesic doses of extended-release oxymorphone (15 mg and 30 mg) 
and controlled-release oxycodone (30 mg and 60 mg) plus placebo in healthy nonde-
pendent recreational opioid users. Subjects received single, double-blind, over- 
encapsulated, intact doses of each opioid or placebo treatment with ≥7 day washout 
period between treatments. Assessments included subjective drug value, a series of 
theoretical choices that forced subjects to select between receiving another dose of the 
same drug to take home or a speciﬁed amount of money in Canadian dollars ($). The 
Subjective Drug Value was administered at the 4, 8 and 24 hour time points of each 
treatment period with a minimum value of $0.25 and a maximum value of $48.00. 
RESULTS: Thirty ﬁve out of forty subjects completed the study. Extended-release 
oxymorphone was associated with statistically lower mean (SE) subjective drug values 
than equianalgesic doses of controlled-release oxycodone: extended-release oxymor-
phone 30 mg $16.85 (2.78) vs. controlled-release oxycodone 60 mg $24.32 (2.78), p 
= 0.013; extended-release oxymorphone 15 mg $9.85 (2.77) vs. controlled-release 
oxycodone 30 mg $25.00 (2.80), p < 0.001. CONCLUSIONS: Oral intact extended-
release oxymorphone had lower subjective drug values than equianalgesic doses of 
controlled-release oxycodone in this exploratory study. The impact of subjective valu-
ation on drug utilization patterns in recreational drug users and patients merits further 
investigation.
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OBJECTIVES: Treatment of acute bleeding episodes in patients with congenital 
hemophilia with inhibitors (CHwI) has transitioned largely to the home setting. The 
study aims to describe patient/caregiver perceptions of acute bleed symptoms, reasons 
for starting/stopping treatment, and choice of medication/dose. METHODS: 
Frequently-bleeding CHwI patients (≥4 bleeding episodes in 3 months) prescribed 
rFVIIa as ﬁrst-line therapy, or their caregivers, completed a daily diary for 3–6 months 
capturing bleeding symptoms and treatment decisions. RESULTS: Thirty-nine patients 
(median age 16.2) reported 194 hemorrhages (131 hemarthroses, 19 muscle, 44 
other). Pain was reported in 78.9% of bleeding episodes (90.1% joint, 89.5% muscle). 
Other recorded symptoms for bleeds (all/joint/muscle) included joint swelling 
(44.8%/65.6%/5.3%), decreased mobility/range of motion (41.2%/48.9%/68.4%), 
heat (21.1%/26.0%/15.8%), other swelling (16.0%/6.9%/47.4%), irritability 
(14.9%/16.8%/10.5%), bleeding (12.4%/7.6%/5.3%), and redness (10.3%/6.1%/ 
10.5%). A majority of patients/caregivers recognized when a bleed started 
(58.4%/58.0%), but were much less clear of when a bleed stopped (43.5%/33.3%). 
Medication was most commonly started by patients/caregivers when a bleed was 
identiﬁed (73.7%/47.4%) or because they were concerned a bleed might start and 
wanted to prevent it early (32.9%/27.6%). Common reasons for delays in starting 
medication by patients included ‘I thought it might not be a bleed’ (48.9%), ‘I wanted 
to see if the bleed progressed’ (46.8%), and ‘I thought it was just joint pain’ (44.7%). 
Most common reasons for caregivers were: ‘I wanted to see if it progressed’ (37.9%), 
‘I didn’t have medication’ (20.7%), and ‘I thought it might not be a bleed’ (17.2%). 
Reasons for stopping medication for patients/caregivers were pain cessation or stabi-
lization (93.9%/54.7%), arrest of swelling progression (60.6%/46.9%), and restora-
tion of mobility (50.0%/35.9%). CONCLUSIONS: Patients/caregivers have difﬁculty 
in determining bleed onset and particularly resolution, both quite necessary for clinical 
trials. Inability for caregivers to assess resolution in children may lead to longer treat-
ment duration seen in DOSE.
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OBJECTIVES: To assess the association between self-reported neuropathic pain sever-
ity and the EQ-5D. METHODS: This study used data from baseline responses from 
2719 participants to 3 longitudinal internet surveys who: 1) reported ≥3 months of 
pDPN/PHN; 2) were receiving a prescription/OTC medication to treat pDPN/PHN; 
and 3) had completed a baseline EQ-5D. Ordered logistic regression models were used 
to assess the association between EQ-5D items and pain severity, adjusting for age, 
gender and years since pDPN/PHN diagnosis. Pain severity was assessed using the 
11-point pain-intensity numerical rating scale (0 = no pain to 10 = pain as bad as you 
can imagine). The likelihood-ratio test was used to test the proportionality of odds 
assumption. RESULTS: Respondents were 56% female, mean age 55.48 (±10.65) 
years, had pDPN/PHN duration for 5.1 (±4.7) years, and had mean (median) pain 
severity of 5.7 (6.0). The proportionality of odds assumption was not rejected (P < 
0.05). Compared with reference pain severity = 0, participants with greater pain sever-
ity were more likely to report greater health deﬁcits on the EQ-5D items. All covariates 
were signiﬁcantly (P ≤ 0.05) associated with the EQ-5D items except for age on 
“Mobility” and lower pain severity (1 or 2) on “Mobility” and “Self-care”. As 
expected, item “Pain/discomfort” demonstrated greater association with pDPN/PHN 
pain severity. For instance, relative to respondents with pain severity = 0, respondents 
with pain severity = 1 and = 10 were 2.52 (p = 0.026) and 1954.33 (p < 0.0001) times 
more likely to report more severe “pain/discomfort”, respectively. In comparison, 
respondents with pain severity = 10 were 13.05, 13.83, 24.50, and 38.83 times more 
likely to report more difﬁculties on “Self-care”, “Anxiety/depression” “Mobility”, and 
“Usual activities” (p < 0.0001), respectively, relative to respondents with pain severity 
= 0. CONCLUSIONS: A strong association exists between self-reported neuropathic 
pain severity and the EQ-5D. The EQ-5D is sensitive in detecting health disparities 
among moderate to severe chronic pDPN/PHN patients.
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OBJECTIVES: Patients with congenital hemophilia with inhibitors (CHwI) experience 
acute bleeds that are managed with bypassing agents such as rFVIIa. Home treatment 
and dosing patterns in the US remain unknown. This study aimed to assess differences 
between prescribed/actual rFVIIa dosing in frequently-bleeding CHwI patients (≥4 
bleeds/3 months) prescribed ﬁrst-line therapy with rFVIIa. METHODS: Patients or 
caregivers recorded daily diaries including the details of all bypassing agent infusions 
on bleed/treatment days for 3–6 months. RESULTS: Median (range) initial rFVIIa 
dose prescribed by physicians for joint, muscle and other bleeds was 167.5 mcg/kg 
(61.0–289.0). Approximately 50% of initial rFVIIa doses prescribed were ≥160 mcg/
kg and 35% were ≥240 mcg/kg. Median prescribed additional rFVIIa dose for all 
bleeds was 90 mcg/kg (61.0–270.0) at an interval of 2.5–3 (1–24) hours. Median 
(range) actual initial rFVIIa dose reported by patients for 158 bleeds was 211.6 mcg/
kg (59.3–400.0), with total dose per episode of 694.9 mcg/kg (74.1–21,257.4). 
Patient/caregiver reported average dose per bleed was 146.1 mcg/kg (39.5–400) across 
5 (1.0–106.0) infusions. The initial rFVIIa dose was higher for joint bleeds (223.0 mcg/
kg [59.3–400.0]), compared with muscle (148.1 mcg/kg [74.1–300.0]; P = 0.07) and 
other bleeds (166.7 mcg/kg [64.0–400.0]; P = 0.02). Initial rFVIIa dose was ≥160 mcg/
kg in 65% of all bleeds and 73% of joint bleeds. The second dose for all bleeds was 
131.5 mcg/kg (29.6–379.7) with 43% being ≥160 mcg/kg and 27% ≥240 mcg/kg. 
CONCLUSIONS: Prescription data from the DOSE study demonstrate higher initial 
dosing for all bleed types than the package insert recommended dose of 90 mcg/kg. 
Additional prescribed dosing (where required) more closely conformed to package 
insert recommendations. Patient/caregiver reported actual dosing was generally higher 
than that prescribed, both for initial dosing (particularly for joint bleeds) and for 
additional dosing. These data suggest that patients/caregivers may have adopted home 
treatment strategies based upon individual responses and experience.
